Xinzheng Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinzheng Dai has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Feifan Yao
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key laboratory of Hepatobiliary cancers (The First Affiliated Hospital of Nanjing Medical University), Nanjing, Jiangsu Province, China
3 shared publicationsJiali Xu
Department of Anesthesiology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Province, China
3 shared publicationsJing Xu
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3 shared publicationsKai Yu
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key laboratory of Hepatobiliary cancers (The First Affiliated Hospital of Nanjing Medical University), Nanjing, Jiangsu Province, China
3 shared publications- Qing Li
Department of Hepatobiliary Surgery, The First Affiliated Hospital with Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Key Laboratory of Hepatobiliary Tumors, National Health Commission, Jiangsu Provincial Medical Innovation Center, Jiangsu Provincial Medical Key Laboratory, Nanjing Medical University, Nanjing, Jiangsu Province, China
3 shared publications Ruizhi Zhang
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key laboratory of Hepatobiliary cancers (The First Affiliated Hospital of Nanjing Medical University), Nanjing, Jiangsu Province, China
3 shared publications
Latest Publications
- 3 May 2024
- Published by Elsevier in Cancer Letters
- Vol. 593, 216935
CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma
- 3 May 2024
- Published by Elsevier in Cancer Letters
- Vol. 593, 216935
CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma
- Open Access
- 28 November 2023
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (3) , 399-421
Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis
- 28 November 2023
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (3) , 399-421
Open AccessHepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis
- Top Cited Papers
- 12 October 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (1) , 82-98
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma
- 12 October 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (1) , 82-98
Top Cited PapersEndothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma
- Open Access
- 28 August 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-16
Orosomucoid 1 promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing macrophage M2 polarization
Approximately 25–30% of those affected by colorectal cancer (CRC), the most prevalent gastrointestinal malignancy, develop metastases. The survival rate of patients with liver metastasis of CRC (CRLM) remains low owing to its unpredictability and a lack of biomarkers that can be applied to distinguish groups at higher risk for CRLM among patients with CRC. Therefore, our study aimed to find biomarkers that can predict the risk of CRLM. Screening of the Gene Expression Omnibus database, supported by an analysis of clinically obtained tissue and serum data using qPCR and ELISA, in an attempt to identify relevant biomarkers, enabled us to determine that orosomucoid 1 (ORM1) was differentially expressed in liver metastases and primary tumors of patients with CRC. Functionally, overexpression of ORM1 promoted the epithelial-mesenchymal transition and the proliferative, migratory, and invasive activities of MC38 cells and activated the PI3K/AKT signaling pathway. Moreover, MC38 cells overexpressing ORM1 enhanced the tumor immune microenvironment by promoting macrophage M2 polarization and elevating interleukin-10 (IL-10) expression. In vivo experiments further confirmed in vitro results, indicating that liver metastases elevated by ORM1 were partially attenuated by the depletion of macrophages or IL-10. Considered together, ORM1 promotes CRC progression and liver metastasis by regulating tumor cell growth and inducing macrophage M2 polarization, which mediates tumor immune tolerance, and thus acts as a potential predictive marker and therapeutic target in CRLM.
- 28 August 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-16
Open AccessOrosomucoid 1 promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing macrophage M2 polarization
Approximately 25–30% of those affected by colorectal cancer (CRC), the most prevalent gastrointestinal malignancy, develop metastases. The survival rate of patients with liver metastasis of CRC (CRLM) remains low owing to its unpredictability and a lack of biomarkers that can be applied to distinguish groups at higher risk for CRLM among patients with CRC. Therefore, our study aimed to find biomarkers that can predict the risk of CRLM. Screening of the Gene Expression Omnibus database, supported by an analysis of clinically obtained tissue and serum data using qPCR and ELISA, in an attempt to identify relevant biomarkers, enabled us to determine that orosomucoid 1 (ORM1) was differentially expressed in liver metastases and primary tumors of patients with CRC. Functionally, overexpression of ORM1 promoted the epithelial-mesenchymal transition and the proliferative, migratory, and invasive activities of MC38 cells and activated the PI3K/AKT signaling pathway. Moreover, MC38 cells overexpressing ORM1 enhanced the tumor immune microenvironment by promoting macrophage M2 polarization and elevating interleukin-10 (IL-10) expression. In vivo experiments further confirmed in vitro results, indicating that liver metastases elevated by ORM1 were partially attenuated by the depletion of macrophages or IL-10. Considered together, ORM1 promotes CRC progression and liver metastasis by regulating tumor cell growth and inducing macrophage M2 polarization, which mediates tumor immune tolerance, and thus acts as a potential predictive marker and therapeutic target in CRLM.
- 1 August 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 85, 106580
N-acetylcysteine alleviates liver injury by suppressing macrophage-mediated inflammatory response post microwave ablation
- 1 August 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 85, 106580
N-acetylcysteine alleviates liver injury by suppressing macrophage-mediated inflammatory response post microwave ablation
IL‐2/IL‐6 ratio correlates with liver function and recovery in acute liver injury patients
Acute liver injury can result from a number of different diseases. Inflammatory cytokines are known to be involved in the development of this condition; however, their precise roles and effects on liver function remain unclear. The goal of this study was to determine the relationship between serum cytokine levels and both the severity of liver damage and recovery in acute liver injury. We enrolled 100 patients with acute liver injury caused by drug application who were hospitalized from September 2012 to September 2017 and measured serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the cytokines, interleukin (IL)‐2 and IL‐6, before and after clinical therapy. Our results indicate that IL‐2 and IL‐6 levels are altered significantly following clinical therapy. However, with the exception of an association between IL‐2 and ALT, we found no correlation between the differences in cytokine levels pre‐ and post‐therapy and recovery of liver function. In contrast, we observed that pre‐ vs post‐treatment difference in the IL‐2/IL‐6 ratio negatively correlates with the pre‐ vs post‐treatment difference in ALT and AST values, and positively correlates with ALT and AST at 1‐month post‐discharge. Thus, our data suggest that IL‐2/IL‐6 ratio may represent a novel predictor for the prognosis of liver injury.
IL‐2/IL‐6 ratio correlates with liver function and recovery in acute liver injury patients
Acute liver injury can result from a number of different diseases. Inflammatory cytokines are known to be involved in the development of this condition; however, their precise roles and effects on liver function remain unclear. The goal of this study was to determine the relationship between serum cytokine levels and both the severity of liver damage and recovery in acute liver injury. We enrolled 100 patients with acute liver injury caused by drug application who were hospitalized from September 2012 to September 2017 and measured serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the cytokines, interleukin (IL)‐2 and IL‐6, before and after clinical therapy. Our results indicate that IL‐2 and IL‐6 levels are altered significantly following clinical therapy. However, with the exception of an association between IL‐2 and ALT, we found no correlation between the differences in cytokine levels pre‐ and post‐therapy and recovery of liver function. In contrast, we observed that pre‐ vs post‐treatment difference in the IL‐2/IL‐6 ratio negatively correlates with the pre‐ vs post‐treatment difference in ALT and AST values, and positively correlates with ALT and AST at 1‐month post‐discharge. Thus, our data suggest that IL‐2/IL‐6 ratio may represent a novel predictor for the prognosis of liver injury.